<DOC>
	<DOCNO>NCT01225822</DOCNO>
	<brief_summary>The primary objective study establish dose-response relationship regard efficacy safety BIBR 1048 ( 50 mg bi die ( b.i.d ) , 150 mg b.i.d , 225 mg b.i.d . 300 mg quaque die ( q.d ) ) prevent venous thromboembolism ( VTE ) patient undergo primary elective total hip knee replacement .</brief_summary>
	<brief_title>BIBR 1048 Dose Range Finding Study Prevention Venous Thromboembolism Patients With Primary Elective Total Hip Knee Replacement Surgery</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criterion 1 . Patients schedule undergo primary elective total hip knee replacement . 2 . Male female 18 year old . 3 . Patients weigh least 40 kg . 4 . Written inform consent study participation . Exclusion criteria 1 . Bleeding diathesis , constitutional acquire coagulation disorder . 2 . Major surgery trauma ( e.g. , hip fracture ) within last 3 month . 3 . Cardiovascular disease 4 . Any history haemorrhagic stroke , intracranial intraocular bleed cerebral ischaemic attack last 24 hour / cardiovascular pathological finding . 5 . Deep vein thrombosis ( DVT ) , gastrointestinal pulmonary bleeding , gastric duodenal ulcer within last year . 6 . History acute intracranial disease 7 . Liver disease 8 . Renal disease 9 . Use longterm anticoagulant antiplatelet drug within 7 day prior hip/knee replacement operation . 10 . Premenopausal woman surgically steriles , nurse childbearing potential practising acceptable method birth control 11 . Known allergy contrast medium 12 . Thrombocytopenia 13 . Allergy heparin . 14 . Active malignant disease current cytostatic treatment . 15 . Treatment investigational drug past month . 16 . Leg amputee 17 . Known alcohol drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>